BAY 73-6691
| CAS No. | 794568-92-6 | Cat. No. | BCP20762 |
| Name | BAY 73-6691 | ||
| Synonyms | BAY-73-6691; BAY736691; BAY73-6691; (R)-Bay-73-6691; | ||
| Formula | C15H12ClF3N4O | M. Wt | 356.73 |
| Description | BAY 73-6691 is a drug developed by Bayer for the treatment of Alzheimer's disease. It was the first compound developed that acts as a phosphodiesterase inhibitor selective for the PDE9A subtype. The PDE9A enzyme is expressed primarily in the brain, with high concentrations in the cerebellum, neocortex, striatum, and hippocampus, and acts to limit the cGMP-mediated signal transduction which occurs following glutamate binding to NMDA receptors. | ||
| Pathways | Protease/Metabolic Enzyme | ||
| Targets | Phosphodiesterase/PDE | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.